Sweena M Chaudhari1, Judith C Sluimer1, Miriam Koch1, Thomas L Theelen1, Helga D Manthey1, Martin Busch1, Celia Caballero-Franco1, Frederick Vogel1, Clément Cochain1, Jaroslav Pelisek1, Mat J Daemen1, Manfred B Lutz1, Agnes Görlach1, Stephan Kissler1, Heike M Hermanns1, Alma Zernecke2. 1. From the Institute of Clinical Biochemistry and Pathobiochemistry, University Hospital Würzburg (S.M.C., M.K., C.C., A.Z.), Rudolf Virchow Center (H.D.M., M.B., H.M.H.), Institute of Virology and Immunobiology (M.B.L.), and Division of Hepatology, Medical Clinic II, University Hospital Würzburg (H.M.H.), University of Würzburg, Würzburg, Germany; Department of Pathology, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands (J.C.S., T.L.T.); Joslin Diabetes Center, Harvard Medical School, Boston, MA (C.C.-F., S.K.); Experimental and Molecular Pediatric Cardiology, German Heart Center Munich, TU Munich, Munich, Germany (F.V., A.G.); Department of Vascular and Endovascular Surgery, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany (J.P.); and Department of Pathology, Amsterdam Medical Centre, Amsterdam, The Netherlands (M.J.D.). 2. From the Institute of Clinical Biochemistry and Pathobiochemistry, University Hospital Würzburg (S.M.C., M.K., C.C., A.Z.), Rudolf Virchow Center (H.D.M., M.B., H.M.H.), Institute of Virology and Immunobiology (M.B.L.), and Division of Hepatology, Medical Clinic II, University Hospital Würzburg (H.M.H.), University of Würzburg, Würzburg, Germany; Department of Pathology, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands (J.C.S., T.L.T.); Joslin Diabetes Center, Harvard Medical School, Boston, MA (C.C.-F., S.K.); Experimental and Molecular Pediatric Cardiology, German Heart Center Munich, TU Munich, Munich, Germany (F.V., A.G.); Department of Vascular and Endovascular Surgery, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany (J.P.); and Department of Pathology, Amsterdam Medical Centre, Amsterdam, The Netherlands (M.J.D.). alma.zernecke@uni-wuerzburg.de.
Abstract
OBJECTIVE: Although immune responses drive the pathogenesis of atherosclerosis, mechanisms that control antigen-presenting cell (APC)-mediated immune activation in atherosclerosis remain elusive. We here investigated the function of hypoxia-inducible factor (HIF)-1α in APCs in atherosclerosis. APPROACH AND RESULTS: We found upregulated HIF1α expression in CD11c(+) APCs within atherosclerotic plaques of low-density lipoprotein receptor-deficient (Ldlr(-/-)) mice. Conditional deletion of Hif1a in CD11c(+) APCs in high-fat diet-fed Ldlr(-/-) mice accelerated atherosclerotic plaque formation and increased lesional T-cell infiltrates, revealing a protective role of this transcription factor. HIF1α directly controls Signal Transducers and Activators of Transcription 3 (Stat3), and a reduced STAT3 expression was found in HIF1α-deficient APCs and aortic tissue, together with an upregulated interleukin-12 expression and expansion of type 1 T-helper (Th1) cells. Overexpression of STAT3 in Hif1a-deficient APCs in bone marrow reversed enhanced atherosclerotic lesion formation and reduced Th1 cell expansion in chimeric Ldlr(-/-) mice. Notably, deletion of Hif1a in LysM(+) bone marrow cells in Ldlr(-/-) mice did not affect lesion formation or T-cell activation. In human atherosclerotic lesions, HIF1α, STAT3, and interleukin-12 protein were found to colocalize with APCs. CONCLUSIONS: Our findings identify HIF1α to antagonize APC activation and Th1 T cell polarization during atherogenesis in Ldlr(-/-) mice and to attenuate the progression of atherosclerosis. These data substantiate the critical role of APCs in controlling immune mechanisms that drive atherosclerotic lesion development.
OBJECTIVE: Although immune responses drive the pathogenesis of atherosclerosis, mechanisms that control antigen-presenting cell (APC)-mediated immune activation in atherosclerosis remain elusive. We here investigated the function of hypoxia-inducible factor (HIF)-1α in APCs in atherosclerosis. APPROACH AND RESULTS: We found upregulated HIF1α expression in CD11c(+) APCs within atherosclerotic plaques of low-density lipoprotein receptor-deficient (Ldlr(-/-)) mice. Conditional deletion of Hif1a in CD11c(+) APCs in high-fat diet-fed Ldlr(-/-) mice accelerated atherosclerotic plaque formation and increased lesional T-cell infiltrates, revealing a protective role of this transcription factor. HIF1α directly controls Signal Transducers and Activators of Transcription 3 (Stat3), and a reduced STAT3 expression was found in HIF1α-deficient APCs and aortic tissue, together with an upregulated interleukin-12 expression and expansion of type 1 T-helper (Th1) cells. Overexpression of STAT3 in Hif1a-deficient APCs in bone marrow reversed enhanced atherosclerotic lesion formation and reduced Th1 cell expansion in chimeric Ldlr(-/-) mice. Notably, deletion of Hif1a in LysM(+) bone marrow cells in Ldlr(-/-) mice did not affect lesion formation or T-cell activation. In humanatherosclerotic lesions, HIF1α, STAT3, and interleukin-12 protein were found to colocalize with APCs. CONCLUSIONS: Our findings identify HIF1α to antagonize APC activation and Th1 T cell polarization during atherogenesis in Ldlr(-/-) mice and to attenuate the progression of atherosclerosis. These data substantiate the critical role of APCs in controlling immune mechanisms that drive atherosclerotic lesion development.
Authors: Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson Journal: Cell Date: 2003-03-07 Impact factor: 41.582
Authors: Elke Marsch; Thomas L Theelen; Jasper A F Demandt; Mike Jeurissen; Mathijs van Gink; Robin Verjans; Anique Janssen; Jack P Cleutjens; Steven J R Meex; Marjo M Donners; Guido R Haenen; Casper G Schalkwijk; Ludwig J Dubois; Philippe Lambin; Ziad Mallat; Marion J Gijbels; Johan W M Heemskerk; Edward A Fisher; Erik A L Biessen; Ben J Janssen; Mat J A P Daemen; Judith C Sluimer Journal: Arterioscler Thromb Vasc Biol Date: 2014-09-25 Impact factor: 8.311
Authors: Luis Chávez-Sánchez; Jose E Espinosa-Luna; Karina Chávez-Rueda; María V Legorreta-Haquet; Eduardo Montoya-Díaz; Francisco Blanco-Favela Journal: Arch Med Res Date: 2013-12-08 Impact factor: 2.235
Authors: Eric T Clambey; Eóin N McNamee; Joseph A Westrich; Louise E Glover; Eric L Campbell; Paul Jedlicka; Edwin F de Zoeten; John C Cambier; Kurt R Stenmark; Sean P Colgan; Holger K Eltzschig Journal: Proc Natl Acad Sci U S A Date: 2012-09-17 Impact factor: 11.205
Authors: Ahmed Tawakol; Parmanand Singh; Marina Mojena; María Pimentel-Santillana; Hamed Emami; Megan MacNabb; James H F Rudd; Jagat Narula; José A Enriquez; Paqui G Través; María Fernández-Velasco; Ramón Bartrons; Paloma Martín-Sanz; Zahi A Fayad; Alberto Tejedor; Lisardo Boscá Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-16 Impact factor: 8.311
Authors: Yaw Asare; Miriam Ommer; Florence A Azombo; Setareh Alampour-Rajabi; Marieke Sternkopf; Maryam Sanati; Marion J Gijbels; Corinna Schmitz; Dzmitry Sinitski; Pathricia V Tilstam; Hongqi Lue; André Gessner; Denise Lange; Johannes A Schmid; Christian Weber; Martin Dichgans; Joachim Jankowski; Ruggero Pardi; Menno P J de Winther; Heidi Noels; Jürgen Bernhagen Journal: Proc Natl Acad Sci U S A Date: 2017-03-14 Impact factor: 11.205
Authors: Finosh G Thankam; Joseph G Ayoub; Mohamed M Radwan Ahmed; Aleem Siddique; Thomas C Sanchez; Rafael A Peralta; Thomas J Pennington; Devendra K Agrawal Journal: Transl Res Date: 2020-08-28 Impact factor: 7.012
Authors: Shuang Feng; Neil Bowden; Maria Fragiadaki; Celine Souilhol; Sarah Hsiao; Marwa Mahmoud; Scott Allen; Daniela Pirri; Blanca Tardajos Ayllon; Shamima Akhtar; A A Roger Thompson; Hanjoong Jo; Christian Weber; Victoria Ridger; Andreas Schober; Paul C Evans Journal: Arterioscler Thromb Vasc Biol Date: 2017-09-07 Impact factor: 10.514